Medicare AdvantageCoverageMedium impact
MA08.073t, Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists, VEGF Biosimilars, and Combination VEGF/Angiopoietin-2 (Ang-2) Inhibitors
Independence Blue Cross·Ophthalmology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
This policy update affects intravitreal injections for VEGF antagonists, VEGF biosimilars, and combination VEGF/Ang-2 inhibitors for Medicare Advantage plans. The policy became effective October 1, 2025, but specific changes are not detailed in the summary-only content provided.
Action Required
By October 1, 2025: Billing team should review the full policy document at the provided URL to understand specific changes to intravitreal injection billing requirements for VEGF treatments. Update billing procedures and prior authorization requirements as specified in the complete policy for Medicare Advantage plans.